ApcinteX Ltd.
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2014-06-16
- Employees
- 1
- Market Cap
- -
- Website
- http://www.apcintex.com
Clinical Trials
7
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
- Conditions
- Hemophilia aHemophilia BHemophilia a with InhibitorHemophilia B with Inhibitor
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT06568302
- Locations
- 🇬🇪
ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia
🇲🇩Institute of Oncology, ARENSIA Exploratory Medicine, Chisinau, Moldova, Republic of
The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT05789524
- Locations
- 🇺🇸
University of Colorado School of Medicine, Aurora, Colorado, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, Indiana, United States
A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 3
- Registration Number
- NCT05789537
- Locations
- 🇺🇸
University of Colorado School of Medicine, Aurora, Colorado, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)
- Conditions
- Hemophilia aHemophilia B
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT05605678
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸East Carolina univeristy, Greenville, South Carolina, United States
🇦🇲Centre of Haematology named after prof. R. O. Yeolian, Yerevan, Armenia
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- ApcinteX Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT04073498
- Locations
- 🇲🇩
Arensia Clinical Research Unit, Chisinau, Moldova, Republic of
🇬🇧Simbec Research Ltd, Merthyr Tydfil, Cardiff, United Kingdom
News
Hemophilia B Therapeutics: Advances in Clinical Trials and Emerging Therapies
Several companies are actively involved in developing therapies for Hemophilia B, with Belief Biomed's drug candidates reaching Phase III clinical trials.